ELECLAZINE
GS-6615
Molecular Formula: | C21H16F3N3O3 |
---|---|
Molecular Weight: | 415.372 g/mol |
1443211-72-0
4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-5-one
4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3,4,5- tetrahydro-1,4- benzoxazepin-5-one
7-(4-(Trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one
1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl]-
Eleclazine; UNII-PUY08529FK; 1443211-72-0; GS-6615; PUY08529FK; 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-on
- Phase III Long QT syndrome
INGREDIENT | UNII | CAS |
---|---|---|
Eleclazine Hydrochloride | 4R1JP3Q4HI | 1448754-43-5 |
Eleclazine has been used in trials studying the treatment of LQT2 Syndrome, Long QT Syndrome, Ischemic Heart Disease, Ventricular Arrhythmia, and Long QT Syndrome Type 3, among others.
In 2015, orphan drug designation was assigned to the product by the FDA for the treatment of congenital long QT syndrome.
- Originator Gilead Sciences
- Class Antiarrhythmics; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Vasodilators
- Mechanism of Action Sodium channel antagonists
Highest Development Phases
- Phase III Long QT syndrome
- Phase II/III Hypertrophic cardiomyopathy
- Phase II Ventricular arrhythmias
- No development reported
View original post 2,322 more words